Transdermal therapeutic system containing asenapine
The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.
1. A method of treating schizophrenia, the method comprising administering to a subject in need thereof, a transdermal therapeutic system comprising:
a) a polyester backing layer; and
b) an asenapine-containing matrix layer comprising asenapine and a polymer;
wherein
the transdermal therapeutic system has an area of release ranging from 10 to 80 cm 2 ;
the amount of asenapine in the asenapine-containing matrix layer ranges from 2 to about 20% by weight;
the asenapine-containing matrix layer has an area weight ranging from 90 to 230 g/m 2 ; and
wherein the polymer comprises a styrene-isoprene-styrene block copolymer;
further wherein the transdermal therapeutic system provides:
a mean transdermal asenapine release rate of 2.0 to 10 mg/day; and
an asenapine C max value of from 0.5 to 10 ng/ml following administration of the transdermal system to the skin of the subject in need thereof.
2. The method of claim 1 , wherein the asenapine in the asenapine-containing matrix layer is asenapine free base.
3. The method of claim 1 , wherein the asenapine in the asenapine-containing matrix layer is an asenapine salt.
4. The method of claim 1 , wherein the asenapine in the asenapine-containing matrix layer is a mixture of an asenapine salt and asenapine free base.
5. The method of claim 4 , wherein the asenapine salt is asenapine maleate.
6. The method of claim 1 , wherein the transdermal therapeutic system provides an asenapine C max value of from 1 to 8 ng/ml or from 1.5 to 5 ng/ml following administration of the transdermal system to skin of the subject in need thereof.
7. The method of claim 1 , wherein the transdermal therapeutic system further provides an asenapine AUC 0-24 ranging from about 20 [(ng/ml)h] to about 78 [(ng/ml)h] following administration of the system to skin of the subject in need thereof.
8. The method of claim 7 , wherein the transdermal therapeutic system further provides a des-methyl-asenapine AUC 0-24 ranging from about 0.4 [(ng/ml)h] to about 6 [(ng/ml)h] following administration of the system to skin of the subject in need thereof.
9. The method of claim 1 , wherein the transdermal therapeutic system further provides an AUC 0-24 within 10% to 1000% of the steady state AUC 0-24 obtained upon administration of twice daily 5 mg sublingual asenapine following administration of the system to skin of the subject in need thereof.
10. The method of claim 1 , wherein the polymer further comprises a polyisobutylene adhesive.
11. The method of claim 10 , wherein the polymer comprises a polyisobutylene adhesive in an amount not exceeding more than 50% by weight of the matrix layer.
12. The method of claim 1 , wherein the transdermal therapeutic system contains from about 5 to 100 mg asenapine.
13. The method of claim 1 , wherein the amount of asenapine in the asenapine-containing matrix layer ranges from 2 to 4% by weight.
14. The method of claim 1 , wherein the matrix layer further comprises one or more additives selected from the group consisting of a resin, butylated hydroxytoluene, and isopropyl palmitate.
15. The method of claim 1 , wherein the transdermal therapeutic system provides a skin permeation rate of asenapine as measured in a Franz diffusion cell with dermatomed human skin of
0 μg/(cm 2 h) to 10 μg/(cm 2 h) in the first 8 hours,
2 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 8 to hour 24,
3 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 24 to hour 32,
3 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 32 to hour 48,
2 μg/(cm 2 h) to 15 μg/(cm 2 h) from hour 48 to hour 72.
16. The method of claim 1 , wherein the transdermal system is exchanged once per day.
17. The method of claim 1 , wherein fluctuation in asenapine blood plasma concentration is reduced when compared to sublingual administration at steady state.
18. The method of claim 1 , wherein administering the transdermal therapeutic system to the subject in need thereof reduces at least one asenapine-related side effect relative to an equivalent dose of sublingual asenapine.
19. The method of claim 18 , wherein the at least one asenapine-related side effect is selected from the group consisting of fatigue, somnolence, dizziness, oral hypoaesthesia, and a combination thereof.
20. The method of claim 1 , wherein the subject is selected from the group consisting of an adult, an adolescent and a pediatric subject.
21. The method of claim 1 , wherein administering the transdermal system to a subject in need thereof comprises applying the transdermal system to the subject's arm, chest, or back.
22. The method of claim 1 , wherein the C max is achieved at a t max ranging from about 16 to about 24 hours.
23. A method of treating schizophrenia in an adult subject, the method comprising administering to an adult subject in need thereof, a transdermal therapeutic system comprising:
a. a polyester backing layer; and
b. an asenapine-containing matrix layer comprising asenapine, a polyisobutylene adhesive in an amount not exceeding more than 50% by weight of the matrix layer, and a styrene-isoprene-styrene copolymer;
wherein
the transdermal therapeutic system has an area of release ranging from 10 to 80 cm 2 ;
the amount of asenapine in the asenapine-containing matrix layer ranges from 2 to 20 by weight; and
the asenapine-containing matrix layer has an area weight ranging from 90 to 230 g/m 2 ;
further wherein the transdermal therapeutic system provides:
a mean transdermal asenapine release rate of 2.0 to 10 mg/day; and
an asenapine C max value of from 0.5 to 10 ng/ml following administration of the transdermal system to skin of the subject in need thereof.
24. The method of claim 23 , wherein the asenapine in the asenapine-containing matrix layer is selected from asenapine free base, an asenapine salt, and a mixture of an asenapine salt and asenapine free base.
25. The method of claim 24 , wherein the asenapine salt is asenapine maleate.
26. The method of claim 23 , wherein the transdermal therapeutic system provides an asenapine C max value of from 1 to 8 ng/ml or from 1.5 to 5 ng/ml following administration of the transdermal system to skin of the subject in need thereof.
27. The method of claim 23 , wherein the C max is achieved at a t max ranging from about 16 to about 24 hours.
28. The method of claim 1 , wherein the amount of asenapine in the asenapine-containing matrix layer ranges from 3 to 15% by weight.
29. The method of claim 23 , wherein the amount of asenapine in the asenapine-containing matrix layer ranges from 3 to 15% by weight.